UroToday12d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday12d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday18d
SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday18d
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation
SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Kara Watts discussing the role ...
UroToday19d
SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC
(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), ...
UroToday19d
SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy
Radical cystectomy (RC) is a morbid operation with a high rate of perioperative complications. If patients survive their cancer, long-term complications significantly impact their quality of life. Dr.
UroToday19d
SUO 2024: Access to Care for Resource Challenged Populations: Tele-Cystoscopy
SUO annual meeting included a health services session, featuring a presentation by Dr. Tracey Krupski discussing tele-cystoscopy for improving access to care for resource challenged populations. One ...
UroToday19d
SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday19d
SUO 2024: Phase 1B/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...
UroToday20d
SUO 2024: Testosterone Supplementation After Treatment for Localized Prostate Cancer
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX between December 3 rd – 6 th, 2024 was host to a prostate cancer session. Dr. Mohit Khera discussed the use ...
UroToday20d
SUO 2024: Artificial Intelligence in RCC Diagnosis and Treatment
SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Nicholas Kavoussi discussing artificial ...
UroToday20d
SUO 2024: Strategies for RPLND in Metastatic Testicular Seminoma
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to a session addressing ...